Muscular Dystrophy News Home | Muscular Dystrophy News
Nov 8, 2024 · Sarepta stops development of exon 51-skipping therapy for DMD. Despite positive trial data, Sarepta Therapeutics has decided to stop the clinical development of SRP-5051 (vesleteplirsen), an exon 51-skipping therapy for some people with …
Life Expectancy Increasing for DMD Patients, 40-year Analysis Finds
Feb 1, 2022 · Survival probabilities decreased with age. It was 99.8% at age 10, 59.5% at age 20, 26.1% at age 30, and 13.3% at age 40. Further analysis suggested an improvement in life expectancy over time.
What Is Duchenne Muscular Dystrophy (DMD)?
Jan 19, 2022 · The DMD gene is located on the X chromosome, which is one of the two sex-determining chromosomes in people: usually, females have two X chromosomes, while males have one X chromosome and one Y chromosome. DMD is much more common in males than in females because females get two X chromosomes and therefore copies of the DMD gene — so if one copy is mutated, the other copy is usually able to ...
News Archives - Muscular Dystrophy News
Phase 1/2 trial of del-brax enrolling new, possibly pivotal FSHD group. A new patient group is being enrolled in a Phase 1/2 trial of delpacibart braxlosiran (del-brax), an experimental and potentially disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), its developer, Avidity Biosciences, announced.
Educating all ages about living with muscular dystrophy
Oct 7, 2024 · In my four decades of life with limb-girdle muscular dystrophy, I’ve become comfortable educating everyone I meet about my quality of life and the ways all of us living with chronic, rare conditions have been given a wonderful chance to influence societal views of the disabled community. I’ve found it most effective to keep my talks age-appropriate.
DMD treatment: Exon-skipping therapies - Muscular Dystrophy …
Jun 28, 2023 · Certain regulatory approvals have been granted in the U.S. to four exon-skipping therapies designed to treat amenable patients with Duchenne muscular dystrophy (DMD): Exondys 51, Vyondys 53, Viltepso, and Amondys 45.These accelerated approvals were based on early clinical biomarker data showing the therapies can increase production of dystrophin protein, which implies they are likely to ...
SRP-9004 for limb-girdle muscular dystrophy
Jul 31, 2024 · How does SRP-9004 work? LGMD type 2D (LGMD2D), also known as LGMDR3, is a type of muscular dystrophy that’s caused by mutations in the SGCA gene, which provides instructions to make the alpha subunit of the sarcoglycan protein complex.. Normally located in the cellular membrane surrounding muscle cells, this complex helps maintain the structure of muscle tissue by binding to and stabilizing ...
Duchenne muscular dystrophy: Exercise and physical therapy
Jun 17, 2024 · A physical therapist knowledgeable about DMD and progressive muscle weakness and other DMD symptoms can create a therapeutic exercise program that safely stretches and strengthens the body. They also can show you how to use assistive devices such as mobility aids and orthotic devices.. Benefits of physical therapy for people with DMD
Duvyzat (givinostat) for Duchenne muscular dystrophy
Apr 4, 2024 · What is Duvyzat for Duchenne muscular dystrophy? Duvyzat (givinostat) is an oral therapy approved in the U.S. for adults and children, ages 6 and older, with Duchenne muscular dystrophy (DMD). Developed by Italfarmaco, it aims to reduce inflammation and muscle loss in people with DMD, ultimately working to slow disease progression.
Support Groups – Muscular Dystrophy News Forums
This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.